Advertisement

Vimentin Expression in Tumor Microenvironment Predicts Survival in Pancreatic Ductal Adenocarcinoma: Heterogeneity in Fibroblast Population

  • Hiromitsu Maehira
  • Toru MiyakeEmail author
  • Hiroya Iida
  • Aya Tokuda
  • Haruki Mori
  • Daiki Yasukawa
  • Ken-ichi Mukaisho
  • Tomoharu Shimizu
  • Masaji Tani
Translational Research and Biomarkers

Abstract

Background

The tumor microenvironment, including cancer-associated fibroblasts (CAFs), plays various clinical roles in cancer growth. CAFs are a heterogeneous population and express a variety of mesenchymal markers. However, the clinical roles for CAFs expressing different markers in pancreatic ductal adenocarcinoma (PDAC) remain unknown.

Methods

We reviewed 67 resected PDAC patients who had not received preoperative therapy. Each primary tumor was analyzed for vimentin and α-smooth muscle actin (α-SMA) expression by immunohistochemical and dual immunofluorescence staining.

Results

There was no correlation between the percentage of cells expressing vimentin and α-SMA in the tumor stroma (Pearson’s correlation coefficient: r = 0.171). Higher vimentin expression (p = 0.018) was associated with significantly shorter overall survival in PDAC patients. Using dual immunofluorescence staining, vimentin-positive CAFs were divided into two subpopulations: co-expression of α-SMA, and no co-expression of α-SMA. In PDAC, the level of co-expression had no effect on survival using univariate analysis (median survival time, 33.3 months for low co-expression vs. 18.2 months for high co-expression; log-rank, p = 0.143). However, multivariate analysis clarified that CAFs expressing vimentin alone was an independent predictor of poor survival (p = 0.014; hazard ratio, 2.305; 95% confidence interval, 1.181–4.497).

Conclusions

Vimentin-positive CAFs without co-expression of α-SMA were associated with poor survival in PDAC, and CAFs possessed molecular and functional heterogeneity in this disease.

Notes

Acknowledgment

None.

Authors’ Contribution

H. Maehira and T.M. described and designed the article. M.T. revised the article. H. Maehira and K.M performed microscopic evaluation. H.I., A.T., H. Mori, D.Y., and T.S. performed the surgery and postoperative management. All authors read and approved the final article.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Disclosure

The authors declare that they have no conflicts of interest.

Supplementary material

10434_2019_7891_MOESM1_ESM.tif (192 kb)
Supplementary Fig. 1 Receiver operating characteristic (ROC) curve of Vimentin expression rate (a), co-expression rate of α-SMA and Vimentin (b), single α-SMA expression (c), and single Vimentin expression (d) for alive or dead analysis at the median follow-up time. The areas under the ROC are 0.604 (95% CI, 0.448–0.760), 0.538 (95% CI, 0.396–0.681), 0.655 (95% CI, 0.524–0.786), and 0.598 (95% CI, 0.452–0.743), respectively (TIFF 191 kb)
10434_2019_7891_MOESM2_ESM.tif (107 kb)
Supplementary Fig. 2 Kaplan–Meier analyses of RFS (a) and OS (b), according to the CAF number in the tumor, and of RFS (c) and OS (d), according to the CAF number per tumor area, as determined by dual IF staining. CAF cancer-associated fibroblasts; RFS recurrent-free survival; OS overall survival; IF immunofluorescence (TIFF 106 kb)
10434_2019_7891_MOESM3_ESM.tif (75 kb)
Supplementary Fig. 3 Kaplan–Meier analyses of RFS (a) and OS (b) according to the degree of α-SMA single expression in the central part of the tumor stroma, as determined by dual IF staining. RFS recurrent-free survival; OS overall survival; α-SMA alpha-smooth muscle actin; IF immunofluorescence (TIFF 74 kb)

References

  1. 1.
    Kraman M, Bambrough PJ, Arnold JN, et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science. 2010.  https://doi.org/10.1126/science.1195300.CrossRefPubMedGoogle Scholar
  2. 2.
    Liao D, Luo Y, Markowitz D, Xiang R, Reisfeld RA. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS One. 2009.  https://doi.org/10.1371/journal.pone.0007965.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014.  https://doi.org/10.3322/caac.21208.CrossRefPubMedGoogle Scholar
  4. 4.
    Neesse A, Michl P, Frese KK, et al. Stromal biology and therapy in pancreatic cancer. Gut. 2011.  https://doi.org/10.1136/gut.2010.226092.CrossRefPubMedGoogle Scholar
  5. 5.
    Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6:392–401.CrossRefGoogle Scholar
  6. 6.
    Neesse A, Bauer CA, Öhlund D, et al. Stromal biology and therapy in pancreatic cancer: ready for clinical translation? Gut. 2019.  https://doi.org/10.1136/gutjnl-2018-316451.CrossRefPubMedGoogle Scholar
  7. 7.
    Sugimoto H, Mundel TM, Kieran MW, Kalluri R. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther. 2006;5:1640–6.CrossRefGoogle Scholar
  8. 8.
    Neuzillet C, Tijeras-Raballand A, Ragulan C, et al. Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma. J Pathol. 2019.  https://doi.org/10.1002/path.5224.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016.  https://doi.org/10.1038/nrc.2016.73.CrossRefPubMedGoogle Scholar
  10. 10.
    Bu L, Baba H, Yoshida N, et al. Biological heterogeneity and versatility of cancer-associated fibroblasts in the tumor microenvironment. Oncogene. 2019.  https://doi.org/10.1038/s41388-019-0765-y.CrossRefPubMedGoogle Scholar
  11. 11.
    Nielsen MF, Mortensen MB, Detlefsen S. Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells. World J Gastroenterol. 2016.  https://doi.org/10.3748/wjg.v22.i9.2678.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Öhlund D, Handly-Santana A, Biffi G, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med. 2017.  https://doi.org/10.1084/jem.20162024.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Ikuta D, Miyake T, Shimizu T, et al. Fibrosis in metastatic lymph nodes is clinically correlated to poor prognosis in colorectal cancer. Oncotarget. 2018; 9: 29574–29586.CrossRefGoogle Scholar
  14. 14.
    Erez N, Truitt M, Plson P, Arron ST, Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell. 2010.  https://doi.org/10.1016/j.ccr.2009.12.041.CrossRefPubMedGoogle Scholar
  15. 15.
    Sobin LH, Gospodarowicz MK, Wittekind C, eds. International Union Against Cancer. TNM classification of malignant tumors, 7th edn. New Jersey: Wiley-Blackwell, 2009.Google Scholar
  16. 16.
    Nitta T, Mitsuhashi T, Hatanaka Y, et al. Prognostic significance of epithelial-mesenchymal transition-related markers in extrahepatic cholangiocarcinoma: comprehensive immunohistochemical study using a tissue microarray. Br J Cancer. 2014.  https://doi.org/10.1038/bjc.2014.415.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013.  https://doi.org/10.1038/bmt.2012.244.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Maehira H, Iida H, Mori H, et al. Computed tomography enhancement pattern of the pancreatic parenchyma predicts postoperative pancreatic fistula after pancreaticoduodenectomy. Pancreas. 2019.  https://doi.org/10.1097/MPA.0000000000001229.CrossRefPubMedGoogle Scholar
  19. 19.
    Iida H, Maehira H, Mori H, et al. Serum procalcitonin as a predictor of infectious complication after pancreaticoduodenectomy: review of the literature and our experience. Surg Today. 2019.  https://doi.org/10.1007/s00595-019-01811-y.CrossRefPubMedGoogle Scholar
  20. 20.
    Iida H, Tani M, Maehira H, et al. Postoperative pancreatic swelling predicts pancreatic fistula after pancreaticoduodenectomy. Am Surg. 2019;85:321–6.PubMedGoogle Scholar
  21. 21.
    Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011.  https://doi.org/10.1056/NEJMoa1011923.CrossRefPubMedGoogle Scholar
  22. 22.
    Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013.  https://doi.org/10.1056/NEJMoa1304369.CrossRefGoogle Scholar
  23. 23.
    Fujita H, Ohuchida K, Mizumoto K, et al. Alpha-smooth muscle actin expressing stroma promotes an aggressive tumor biology in pancreatic ductal adenocarcinoma. Pancreas. 2010.  https://doi.org/10.1097/MPA.0b013e3181dbf647.CrossRefPubMedGoogle Scholar
  24. 24.
    Sinn M, Denkert C, Striefler JK, et al. α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study. Br J Cancer. 2014.  https://doi.org/10.1038/bjc.2014.495.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Özdemir BC, Pentcheva-Hoang T, Carstens JL, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014.  https://doi.org/10.1016/j.ccr.2014.04.005.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Rhim AD, Oberstein PE, Thomas DH, et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell. 2014.  https://doi.org/10.1016/j.ccr.2014.04.021 CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Kawase T, Yasui Y, Nishina S, et al. Fibroblast activation protein-α-expressing fibroblasts promote the progression of pancreatic ductal adenocarcinoma. BMC Gastroenterol. 2015.  https://doi.org/10.1186/s12876-015-0340-0.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Shi M, Yu DH, Chen Y, et al. Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance. World J Gastroenterol. 2012.  https://doi.org/10.3748/wjg.v18.i8.840.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Whittle MC, Hingorani SR. Fibroblasts in pancreatic ductal adenocarcinoma: biological mechanisms and therapeutic targets. Gastroenterology. 2019.  https://doi.org/10.1053/j.gastro.2018.12.044.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  • Hiromitsu Maehira
    • 1
  • Toru Miyake
    • 1
    Email author
  • Hiroya Iida
    • 1
  • Aya Tokuda
    • 1
  • Haruki Mori
    • 1
  • Daiki Yasukawa
    • 1
  • Ken-ichi Mukaisho
    • 2
  • Tomoharu Shimizu
    • 1
  • Masaji Tani
    • 1
  1. 1.Department of SurgeryShiga University of Medical ScienceOtsu-shiJapan
  2. 2.Department of Molecular and Diagnostic PathologyShiga University of Medical ScienceShigaJapan

Personalised recommendations